First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

MLA

A. Vergnenegre, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Feb. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....36f7125153a7a538998a341b2f60e83e&authtype=sso&custid=ns315887.

APA

A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, … Gregory A. Otterson. (2022). First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

Chicago

A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, et al. 2022. “First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial,” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....36f7125153a7a538998a341b2f60e83e&authtype=sso&custid=ns315887.